ChromaGenix and Sunresin have announced a new partnership to expand access to AAV purification technologies for cell and gene therapy developers across Asia.
The collaboration supports ChromaGenix’s continued growth and strengthens regional access to advanced chromatography solutions, commercial engagement and technical support for customers working in viral vector manufacturing.
Through the partnership, Sunresin will support customer access and regional engagement across Asia, helping process development and manufacturing teams connect with ChromaGenix AAV purification technologies through a local commercial and technical support pathway.
The partnership brings together complementary strengths from both companies. ChromaGenix contributes advanced purification technology for complex biologics, while Sunresin brings chromatography experience, manufacturing capability, regional market presence and customer support infrastructure across Asia.
Expanding regional support for AAV purification
AAV manufacturing places significant demands on downstream processing. Developers must balance vector recovery, impurity clearance, scalability, workflow consistency and practical process implementation.
For teams evaluating new purification technologies, regional support can be an important part of the adoption pathway. Access to local expertise, commercial coordination and technical discussion can help customers assess process fit more efficiently and with greater confidence.
The ChromaGenix and Sunresin partnership is designed to support that need by improving access to AAV purification technologies and strengthening the support structure available to customers across Asia.
"Cell and gene therapy developers need purification technologies that are technically robust, scalable and easier to apply across different AAV programs. Our cooperation with ChromaGenix combines complementary strengths: ChromaGenix’s synthetic ligand-based purification technologies and Sunresin’s expertise in chromatography development, manufacturing, supply reliability and customer support across Asia. It gives customers access to a practical platform for both AAV capture and impurity removal.” - Fred Ghanem, Vice President, Life Sciences, Sunresin
"Broad serotype coverage can simplify downstream development and reduce the need to redesign the capture step for every new AAV candidate,” “AvXcel’s synthetic ligand design also offers developers unique process options, including near-neutral elution conditions that can improve functional recovery, reduce immediate neutralization requirements and shorten time-in-facility compared with more acidic elution workflows. By working with Sunresin, their expertise allows us to improve access to these technologies in Asia while providing customers with the high standard of regional scientific and technical support needed to evaluate them within their own processes.” - Chris Major, CEO, ChromaGenix
Supporting growth in cell and gene therapy manufacturing
Asia continues to be an important region for cell and gene therapy development, viral vector manufacturing and advanced biologic production. By working together, ChromaGenix and Sunresin aim to support customers in the region with chromatography technologies and technical expertise relevant to advanced therapy downstream processing.
The partnership also reflects ChromaGenix’s broader expansion strategy as the company builds commercial reach for its purification technologies and strengthens engagement with customers in key global bioprocessing markets.
A partnership built around access, expertise and customer support
The value of a purification technology depends not only on the underlying chromatography, but also on the ability to evaluate, support and implement it in real process environments.
This partnership is intended to make AAV purification technology more accessible to customers in Asia while creating a stronger regional pathway for technical engagement and customer support.
Evaluating AAV capture? Discover AvXcelTM
Our serotype-agnostic, alkaline-stable AAV affinity resin with flexible elution properties for higher recovery and preserved viral activity.